Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.

28 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Endothelial colony-forming cells show promise against inflammatory bowel disease

New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells' potential to treat inflammatory bowel disease (IBD).

20 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012

Absence of Puma and Bim protein leads to autoimmune diseases

Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs.

7 Sep 2012

Wnt5a protein essential in repairing the intestine's inner lining

Scientists at Washington University School of Medicine in St. Louis have identified a protein essential to repairing the intestine's inner lining.

7 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

Infliximab may offer new hope for people with difficult-to-treat depression

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in the online version of Archives of General Psychiatry.

4 Sep 2012

NFAT protein plays a part in development of acute pancreatitis

It is likely that the protein is also highly significant for other inflammatory diseases. The research results have been published in the American journal Gastroenterology.

1 Sep 2012

The safety of trainee surgeons: an interview with Prof Calvin Coffey

Surgical training begins at an undergraduate medical student level where students are involved in operations to a minor degree, and educated using a combination of didactic and problem-based approaches.

31 Aug 2012

Well-known protein plays central role in development of acute pancreatitis

There is now a clear target for the treatment of acute pancreatitis, according to researchers at Lund University in Sweden, who have discovered that a well-known protein plays a central role in the development of the disease. It is likely that the protein is also highly significant for other inflammatory diseases.

31 Aug 2012

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa, a novel combination therapy for ulcerative colitis (UC).

29 Aug 2012

MR enterography performs well in children with Crohn disease

Parents with children nine years old and older who have Crohn disease should ask their children's doctor about MR enterography as a replacement for small bowel x-rays or CT enterography, a new study indicates.

23 Aug 2012

Study analyzes association between antibiotic use and body mass starting in infancy

Treating very young infants with antibiotics may predispose them to being overweight in childhood, according to a study of more than 10,000 children by researchers at the NYU School of Medicine and the NYU Wagner School of Public Service and published in the online August 21, 2012, issue of the International Journal of Obesity.

22 Aug 2012

VolitionRX to initiate NuQ blood-based tests in colorectal cancer clinical trial

VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium.

22 Aug 2012

HRT linked to ulcerative colitis in postmenopausal women

Taking postmenopausal hormone replacement therapy increases the risk for ulcerative colitis, but not Crohn’s disease, a study shows.

17 Aug 2012

Dendritic cells protect against MS in mouse model

In multiple sclerosis, the immune system attacks nerves in the brain and spinal cord, causing movement problems, muscle weakness and loss of vision. Immune cells called dendritic cells, which were previously thought to contribute to the onset and development of multiple sclerosis, actually protect against the disease in a mouse model, according to a study published by Cell Press in the August issue of the journal Immunity.

17 Aug 2012

PKS-positive E. coli may encourage development of colon cancer

Scientists at the University of Liverpool have identified a type of E. coli bacteria that may encourage the development of colon cancer.

17 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012